Outlook Therapeutics OTLK 深 沪
交易中 11-04 10:43:36 美东时间
1.29
-0.010
-0.77%
华盛通- 最 高1.30
- 今 开1.27
- 成交量 25.28万股
- 最 低 1.24
- 昨 收 1.30
- 总市值 5528.13万
- 52周最高 5.45
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 0.79
- 委 比 -5.54%
- 总股本 4285.37万
- 历史最高 219.20
- 量 比 2.69
- 振 幅 4.62%
- 历史最低 0.79
- 每 手 1
- 风险率 1.14%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Outlook Therapeutics has resubmitted its BLA to the FDA for ONS-5010, an ophthalmic formulation of bevacizumab aimed at treating wet AMD, following feedback from a September 2025 Type A meeting. The company believes this action addresses the issues highlighted in the August 2025 CRL. CEO Bob Jahr emphasized the importance of this step in achieving U.S. approval and highlighted ongoing European commercialization efforts. ONS-5010, branded as LYTEN...
11-03 13:35
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
HC Wainwright & Co. Reiterates Neutral on Outlook Therapeutics, Maintains $1 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and maintains $1 price target.
09-30 19:41
Outlook Therapeutics Completes FDA Meeting on ONS-5010
Outlook Therapeutics ( ($OTLK) ) just unveiled an announcement. On September 29...
09-30 05:33
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Lowers Price Target to $8
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and lowers the price target from $21 to $8.
09-22 17:30
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
- **出席活动** Outlook Therapeutics Inc. 将于2025年9月3日在巴黎举行的第25届EURETINA大会上，参加EURETINA Innovation Spotlight活动，演讲题目为"Optimising the treatment of retinal disease"，由CEO Bob Jahr博士主讲。 - **公司简介** Outlook Therapeutics专注于开发眼科用药LYTENAVA™，这是首个获得欧洲和英国批准用于治疗湿性AMD的贝伐珠单抗制剂。在美国该产品正处于临床研究阶段，若获准将是首个用于治疗视网膜疾病的贝伐珠单抗眼科制剂。
09-03 12:35
FDA Issues Complete Response Letter to Outlook Therapeutics
Outlook Therapeutics ( ($OTLK) ) has issued an update. On August 28, 2025, Outl...
09-03 05:32
Outlook Therapeutics Requests Type A Meeting with FDA
Outlook Therapeutics, Inc. has submitted a Type A Meeting request to the FDA to discuss the recent Complete Response Letter regarding the resubmitted BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab for treating wet AMD. The FDA acknowledged the NORSE TWO pivotal trial met safety and efficacy endpoints but requested additional confirmatory efficacy data. The company believes the meeting will provide clarity on the FDA’s ...
09-02 12:35
Guggenheim Downgrades Outlook Therapeutics to Neutral
Guggenheim analyst Eddie Hickman downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral.
08-30 00:51
